Gleevec — Competitive Intelligence Brief

Gleevec (imatinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor. Area: Oncology.

marketed Kinase Inhibitor Receptor tyrosine-protein kinase erbB-2 Oncology

Target snapshot

Gleevec (imatinib) — Novartis. Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gleevec TARGET	imatinib	Novartis	marketed	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Margenza	MARGETUXIMAB	Macrogenics Inc	marketed	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2020-01-01
Enhertu	trastuzumab-deruxtecan	Daiichi Sankyo	marketed		Receptor tyrosine-protein kinase erbB-2	2019-01-01
Kadcyla	trastuzumab-emtansine	Roche	marketed	Antibody-drug conjugate	Receptor tyrosine-protein kinase erbB-2	2013-01-01
Perjeta	pertuzumab	Roche	marketed	HER2/neu Receptor Antagonist [EPC]	Receptor tyrosine-protein kinase erbB-2	2012-01-01
Perjeta	Perjeta	BioRay Pharmaceutical Co., Ltd.	marketed		Receptor tyrosine-protein kinase erbB-2
Trastuzumab (Herceptin)	trastuzumab-herceptin	Pfizer Inc.	marketed		Receptor tyrosine-protein kinase erbB-2

Recent regulatory actions (last 90 days)

• 2026-03-26 — Kadcyla · FDA · approved · US · Roche

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor class)

1. Novartis · 5 drugs in this class
2. Pfizer · 3 drugs in this class
3. Bayer · 2 drugs in this class
4. Boehringer Ingelheim · 2 drugs in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Exelixis Inc · 1 drug in this class
7. Novartis Pharm · 1 drug in this class
8. Osi Pharms · 1 drug in this class
9. Exelixis · 1 drug in this class
10. Roche · 1 drug in this class